Skip to main content
NewslettersWatchlist

Microbix J(MBX-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.3000
Day High0.3150
Open:0.3050
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
KOL Collaborators Present Microbix HPV Test-Control Results
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix Presents Novel HSV Test Control at EMMD
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix Achieves Essential EU Regulatory Accreditations
GlobeNewswire
Microbix Presenting at Muskoka Capital Conference
AI-generated - The Globe and Mail
Microbix Biosystems: Top 10 Undervalued Biotechnology Industry Stocks (MBX)
GlobeNewswire
Microbix Reports Continued Strong Results for Q3 Fiscal 2024
GlobeNewswire
Microbix Schedules Release of Results for Q3 Fiscal 2024
GlobeNewswire
Microbix Presents HCV FLOQSwab® Format Test Control at ADLM
AI-generated - The Globe and Mail
Microbix Biosystems: Top 10 Undervalued Biotechnology Industry Stocks (MBX)
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix Hosts Minister Nina Tangri to Open Capacity Expansions
AI-generated - The Globe and Mail
Microbix Biosystems: Top 10 Undervalued Biotechnology Industry Stocks (MBX)
GlobeNewswire
Microbix Advances Test-Ingredient Manufacturing Capabilities
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix Reports Strong Results for Q2 Fiscal 2024
GlobeNewswire
Microbix Schedules Release of Results for Q2 Fiscal 2024
Baystreet
Stocks in play: Microbix Biosystems Inc.
GlobeNewswire
Microbix Collaborator Introduces New Lab Accreditation Program
Baystreet
Stocks in play: Microbix Biosystems Inc.

Profile

Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen, QAPs DxTM and Other Includes Kinlytic. It generates maximum revenue from the Antigen QAPs segment. Geographically, it derives a majority of revenue from North America.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.